These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32736660)

  • 1. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
    Tsui JI; Leroux BG; Radick AC; Schramm ZA; Blalock K; Labelle C; Heerema M; Klein JW; Merrill JO; Saxon AJ; Samet JH; Kim TW
    Drug Alcohol Depend; 2021 Oct; 227():108917. PubMed ID: 34399136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
    Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
    Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting.
    Godersky ME; Klein JW; Merrill JO; Blalock KL; Saxon AJ; Samet JH; Tsui JI
    J Addict Med; 2020; 14(4):319-325. PubMed ID: 31972762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
    Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
    Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
    Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
    JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methamphetamine use and illicit opioid use during buprenorphine treatment.
    Kratina-Hathaway Z; Radick AC; Leroux BG; Blalock K; Kim TW; Darnton J; Saxon AJ; Samet JH; Tsui JI
    J Subst Use Addict Treat; 2023 Aug; 151():. PubMed ID: 37811395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.
    Akiyama MJ; Agyemang L; Arnsten JH; Heo M; Norton BL; Schackman BR; Linas BP; Litwin AH
    BMC Infect Dis; 2018 Feb; 18(1):74. PubMed ID: 29426304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
    Sanders NC; Mancino MJ; Gentry WB; Guise JB; Bickel WK; Thostenson J; Oliveto AH
    Exp Clin Psychopharmacol; 2013 Aug; 21(4):294-302. PubMed ID: 23855333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder.
    Bhatraju EP; Radick AC; Leroux BG; Kim TW; Samet JH; Tsui JI
    Am J Drug Alcohol Abuse; 2023 Jul; 49(4):511-518. PubMed ID: 37369019
    [No Abstract]   [Full Text] [Related]  

  • 20. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.